Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Tax Provisions for 14 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 213.43% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 572.36% year-over-year, with the annual reading at $17.5 million for FY2025, 573.01% up from the prior year.
  • Tax Provisions hit $4.0 million in Q4 2025 for Ani Pharmaceuticals, down from $7.2 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $7.2 million in Q3 2025 to a low of -$7.3 million in Q3 2024.
  • Historically, Tax Provisions has averaged -$707263.2 across 5 years, with a median of -$996000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: tumbled 57900.0% in 2022 and later soared 881.82% in 2024.
  • Year by year, Tax Provisions stood at -$6.8 million in 2021, then skyrocketed by 78.02% to -$1.5 million in 2022, then surged by 85.99% to -$208000.0 in 2023, then tumbled by 1575.96% to -$3.5 million in 2024, then skyrocketed by 213.43% to $4.0 million in 2025.
  • Business Quant data shows Tax Provisions for ANIP at $4.0 million in Q4 2025, $7.2 million in Q3 2025, and $2.0 million in Q2 2025.